文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST).

作者信息

Weber E W G, Slappendel R, Hémon Y, Mähler S, Dalén T, Rouwet E, van Os J, Vosmaer A, van der Ark P

机构信息

Sint Maartenskliniek, Nijmegen, France.

出版信息

Eur J Anaesthesiol. 2005 Apr;22(4):249-57. doi: 10.1017/s0265021505000426.


DOI:10.1017/s0265021505000426
PMID:15892401
Abstract

BACKGROUND AND OBJECTIVE: Preoperative epoetin alfa administration decreases transfusion requirements and may reduce transfusion complications, such as postoperative infection due to immune suppression and thus hospitalization time. This study examined the impact of preoperative epoetin alfa administration on postoperative recovery and infection rate. METHODS: In an open randomized controlled multicentre trial in patients undergoing orthopaedic surgery, the effects of preoperative administration of epoetin alfa vs. routine care were compared in six countries. Haemoglobin (Hb) values, transfusions, time to ambulation, time to discharge, infections and safety were evaluated in patients with preoperative Hb concentrations 10-13g dL(-1) (on-treatment population: epoetin n = 460; control n = 235), from study entry until 4-6 weeks after surgery. Outcome was also compared in patients with and without transfusion. RESULTS: Epoetin-treated patients had higher Hb values from the day of surgery until discharge (P < 0.001) and lower transfusion rates (12% vs. 46%; P < 0.001). Epoetin treatment delivered no significant effect on postoperative recovery (time to ambulation, time to discharge and infection rate). However, the time to ambulation (3.8+/-4.0 vs. 3.1+/-2.2days; P < 0.001)and the time to discharge (12.9+/-6.4 vs. 10.2+/-5.0 days; P < 0.001) was longer in the transfused than in the non-transfused patients. Side-effects in both groups were comparable. CONCLUSIONS: Epoetin alfa increases perioperative Hb concentration in mild-to-moderately anaemic patients and thus reduces transfusion requirements. Patients receiving blood transfusions require a longer hospitalization than non-transfused patients.

摘要

相似文献

[1]
Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST).

Eur J Anaesthesiol. 2005-4

[2]
An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty.

Orthopedics. 1999-1

[3]
Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.

Oncologist. 2004

[4]
Efficacy and safety of epoetin alfa in critically ill patients.

N Engl J Med. 2007-9-6

[5]
Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer. Implications for use in gynecologic surgery.

J Reprod Med. 2001-5

[6]
An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.

J Am Med Dir Assoc. 2010-11-11

[7]
A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.

Anticancer Res. 2005

[8]
Preoperative administration of epoetin alfa to reduce transfusion requirements in elderly patients having primary total hip or knee reconstruction.

J South Orthop Assoc. 2000

[9]
Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial.

Br J Cancer. 2006-4-10

[10]
Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy.

Tumori. 2004

引用本文的文献

[1]
Need for preoperative anemia management clinics in Japan: initiatives at a university hospital in the USA.

J Anesth. 2021-10

[2]
Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery.

Cochrane Database Syst Rev. 2020-8-13

[3]
Blood management in fast-track orthopedic surgery: an evidence-based narrative review.

J Orthop Surg Res. 2019-8-20

[4]
Korean clinical practice guideline for perioperative red blood cell transfusion from Korean Society of Anesthesiologists.

Korean J Anesthesiol. 2018-12-5

[5]
A meta-analysis and systematic review evaluating the use of erythropoietin in total hip and knee arthroplasty.

Ther Clin Risk Manag. 2018-7-10

[6]
Current misconceptions in diagnosis and management of iron deficiency.

Blood Transfus. 2017-9

[7]
Perioperative blood management strategies for patients undergoing total knee replacement: Where do we stand now?

World J Orthop. 2017-6-18

[8]
Peri-operative treatment of anaemia in major orthopaedic surgery: a practical approach from Spain.

Blood Transfus. 2017-1-26

[9]
The effectiveness and safety of preoperative use of erythropoietin in patients scheduled for total hip or knee arthroplasty: A systematic review and meta-analysis of randomized controlled trials.

Medicine (Baltimore). 2016-7

[10]
Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.

Blood Transfus. 2016-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索